Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib ascending-dose open-label study of PIT565 in systemic lupus erythematosus
NL-OMON60209Phase 1Suspended
- Sponsor
- Novartis
- Start
- Feb 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PIT565 in systemic lupus erythematosus (SLE), sponsored by Novartis. Started Feb 2025; status: suspended.
02
Drugs
PIT565
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON60209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60209.